Status: Pending
Pasteur-TheraVectys Joint Lab develops anti-tumoral T cell vaccines based on lentiviral vectors to target viral oncogenes or neo-epitopes. In this context, a diverse tumor-specific CD8+ T-cell response to contain growth of polyclonal tumors is required. The quality of the cellular response induced after vaccination is a central issue and is assessed by the T cell repertoire generated. This is defined both by the quantity of specific T cells induced and the diversity of the TCR repertoire. In this project we want to evaluate the impact of a prime-boost protocol on the TCR repertoire. The objectives are: (i) to evaluate the evolution of the frequencies of the induced clonotypes between a prime and a boost (ii) to determine the degree of homology in the V(D)J recombination profile between different individuals after a prime and a boost (iii) to determine the correlation between the diversity of the TCR repertoire observed by sequencing and the measurement of intensity of specific response assessed by ELISpots. All these informations will allow us to evaluate the relevance of a prime-boost strategy with a lentiviral vector.
Submitted: 2023-04-24 11:36 · Last updated: 2024-03-26 10:57